Cognition Therapeutics/$CGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Cognition Therapeutics
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Ticker
$CGTX
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
27
ISIN
US19243B1026
Website
CGTX Metrics
BasicAdvanced
$25M
-
-$0.72
0.74
-
Price and volume
Market cap
$25M
Beta
0.74
52-week high
$0.50
52-week low
$0.22
Average daily volume
2.1M
Financial strength
Current ratio
2.088
Quick ratio
1.937
Long term debt to equity
2.282
Total debt to equity
5.175
Interest coverage (TTM)
-2,681.95%
Profitability
EBITDA (TTM)
-53.532
Management effectiveness
Return on assets (TTM)
-107.53%
Return on equity (TTM)
-161.93%
Valuation
Price to book
2.05
Price to tangible book (TTM)
2.05
Price to free cash flow (TTM)
-0.609
Free cash flow yield (TTM)
-164.30%
Free cash flow per share (TTM)
-66.54%
Growth
Earnings per share change (TTM)
-21.97%
3-year earnings per share growth (CAGR)
-26.27%
CGTX News
AllArticlesVideos
Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer's Disease Surpasses 50% Enrollment Target
GlobeNewsWire·7 days ago
Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer's Disease and Dementia with Lewy Bodies (DLB)
GlobeNewsWire·2 weeks ago
Philanthropic Donor Funds Cognition Therapeutics' Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Cognition Therapeutics stock?
Cognition Therapeutics (CGTX) has a market cap of $25M as of July 07, 2025.
What is the P/E ratio for Cognition Therapeutics stock?
The price to earnings (P/E) ratio for Cognition Therapeutics (CGTX) stock is 0 as of July 07, 2025.
Does Cognition Therapeutics stock pay dividends?
No, Cognition Therapeutics (CGTX) stock does not pay dividends to its shareholders as of July 07, 2025.
When is the next Cognition Therapeutics dividend payment date?
Cognition Therapeutics (CGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Cognition Therapeutics?
Cognition Therapeutics (CGTX) has a beta rating of 0.74. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.